|
|
News Breaks | | | | October 15, 2012 | | 06:34 EDT |  | PCYC | Pharmacyclics triggers another milestone payment for Phase III CLL trial
Pharmacyclics announced that the international, randomized Phase III clinical trial, or CLL3001, of ibrutinib, or PCI-32765, in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL, has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a third $50M milestone payment obligation from Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies, worldwide collaborator on ibrutinib in oncology and sponsor of this CLL3001 trial. | |
|
News For PCYC From The Last 14 Days Check below for free stories on PCYC the last two weeks. |
|
|
| May 20, 2013 | | 14:07 EDT | | PCYC | Pharmacyclics drug designated for orphan status for multiple myeloma treatment
 Subscribe for More Information | | | May 13, 2013 | | 10:09 EDT |  | PCYC | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 06:33 EDT | | PCYC | Pharmacyclics upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information | | | May 7, 2013 | | 06:22 EDT |  | PCYC | Pharmacyclics initiated with a Neutral at Goldman
Subscribe for More Information | |
|
|
|
|
|
|
